Item 1.01 Entry into a Material Definitive Agreement.
On March 6, 2022, Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the
"Company"), entered into a Securities Purchase Agreement (the "Purchase
Agreement") with an investor (the "Purchaser") providing for the private
placement (the "Private Placement") to the Purchaser of 6,857,142 units
(collectively, the "Units"), each Unit consisting of (i) one share of the
Company's common stock, par value $0.005 per share ("Common Stock") (or, in lieu
thereof, one pre-funded warrant to purchase one share of Common Stock (the
"Pre-Funded Warrants")) and (ii) one warrant to purchase one share of Common
Stock (the "Common Warrants" and, together with the Pre-Funded Warrants, the
"Warrants"), for an aggregate purchase price of approximately $12.0 million (or
$1.75 per share of Common Stock or $1.75 less $0.005 per Pre-Funded Warrant).
The closing of the Private Placement occurred on March 9, 2022 (the "Closing").
Each Pre-Funded Warrant has an exercise price of $0.005 per share of Common
Stock, is immediately exercisable and may be exercised at any time and has no
expiration date, and is subject to customary adjustments. The Pre-Funded
Warrants may not be exercised if the aggregate number of shares of Common Stock
beneficially owned by the holder thereof would exceed 9.99% immediately after
exercise thereof.
Each Common Warrant has an exercise price of $1.91 per share, becomes
exercisable six months following the Closing, and expires five-and-one-half
years from the date of issuance, and is subject to customary adjustments. The
Common Warrants may not be exercised if the aggregate number of shares of the
Company's common stock beneficially owned by the holder thereof would exceed
4.99% immediately after exercise thereof, subject to increase to 9.99% at the
option of the holder.
The Company intends to use the net proceeds from the Private Placement for
general working capital purposes.
The securities issued to the Purchaser under the Purchase Agreement were offered
in reliance on an exemption from registration provided by Section 4(a)(2) of the
Securities Act of 1933, as amended (the "Securities Act") and Rule 506 of
Regulation D promulgated thereunder. The Company relied on this exemption from
registration based in part on representations made by the Purchaser, including
that the Purchaser is an "accredited investor", as defined in Rule 501(a)
promulgated under the Securities Act.
Cantor Fitzgerald & Co. served as the placement agent in connection with the
Private Placement, and the Company has agreed to pay customary placement fees of
the placement agent.
The sale of the securities pursuant to the Purchase Agreement has not been
registered under the Securities Act or any state securities laws. The securities
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. Neither this Current Report
on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the
solicitation of an offer to buy the securities described herein or therein.
The Company and the Purchaser also entered into a Registration Rights Agreement,
dated March 6, 2022, pursuant to which the Company has agreed to prepare and
file a registration statement with the Securities and Exchange Commission no
later than 15 days following the date on which the Company files its Annual
Report on Form 10-K for the fiscal year ended December 31, 2021, to register the
resale of the shares of Common Stock included in the Units and the shares of
Common Stock issuable upon exercise of the Warrants. The Company agreed to use
its best efforts to have such registration statement declared effective as
promptly as possible after the filing thereof, subject to certain specified
penalties if timely effectiveness is not achieved.
The foregoing description of the Purchase Agreement, the Pre-Funded Warrants,
the Common Warrants and the Registration Rights Agreement is only a summary and
is qualified in its entirety by reference to the full text of such agreements,
which are filed as Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, to this
Current Report on Form 8-K and are incorporated by reference herein.
Item 3.02 Unregistered Sales of Equity Securities.
The information contained in Item 1.01 of this Current Report on Form 8-K is
hereby incorporated by reference in response to this Item 3.02.
Item 8.01 Other Events.
On March 7, 2022, the Company issued a press release in accordance with Rule
135c promulgated under the Securities Act announcing the Private Placement.
--------------------------------------------------------------------------------
In accordance with Rule 135c(d), a copy of such press release is filed as
Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in
this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Description
Number
10.1 Securities Purchase Agreement, dated as of March 6, 2022, between
Brooklyn ImmunoTherapeutics, Inc. and the purchaser party thereto.
10.2 Form of Pre-Funded Warrant
10.3 Form of Common Stock Warrant
10.4 Registration Rights Agreement, dated as of March 6, 2022, between
Brooklyn ImmunoTherapeutics, Inc. and the purchaser party thereto.
99.1 Press Release dated March 7, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses